Cassava 2.png
Cassava Sciences Names Rick Barry as Chief Executive Officer
09 sept. 2024 08h30 HE | Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced it has concluded its search for a...
Cassava 2.png
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
03 sept. 2024 08h31 HE | Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been...
Cassava 2.png
Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
08 août 2024 08h00 HE | Cassava Sciences, Inc.
$207.3 Million in Cash and Cash Equivalents at June 30, 2024.Company in Advanced Discussions to Resolve SEC Investigation. $40 Million Estimated Loss Contingency Recorded in Q2 for...
Cassava 2.png
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
05 août 2024 09h01 HE | Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today reflected on the passing of long-time board member Sanford Robertson. We are profoundly saddened by the...
Cassava 2.png
Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET
01 août 2024 08h30 HE | Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a...
Cassava 2.png
Cassava Sciences Announces Expansion of Open-Label Extension Trials
30 juil. 2024 08h15 HE | Cassava Sciences, Inc.
Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on...
Cassava 2.png
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
17 juil. 2024 08h00 HE | Cassava Sciences, Inc.
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 ...
Cassava 2.png
Cassava Sciences Issues Statement on Former Science Advisor
28 juin 2024 15h58 HE | Cassava Sciences, Inc.
AUSTIN, Texas, June 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for...
Cassava 2.png
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
10 mai 2024 16h02 HE | Cassava Sciences, Inc.
$126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam.Over 735 Patients Have Completed a Phase 3...
Cassava 2.png
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
08 mai 2024 11h00 HE | Cassava Sciences, Inc.
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”), a biotechnology company focused on Alzheimer’s disease, today announced total gross proceeds of...